Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review.
Biologic therapy
Outcome
Pyoderma gangrenosum
Systematic review
Treatment
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
19 Aug 2024
19 Aug 2024
Historique:
received:
16
07
2024
accepted:
05
08
2024
revised:
16
07
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
epublish
Résumé
Treatment of pyoderma gangrenosum (PG) is challenging due to the absence of standardized guidelines and the lack of evidence-based, effective treatment options. Here, we performed a systematic review to summarize the use of biologics and their efficacy in the treatment of PG. We searched PubMed/MEDLINE, EMBASE, and Cochrane electronic databases from their inception to September 22nd, 2022, and included 82 peer-reviewed studies with a total of 108 patients. Infliximab, adalimumab, and etanercept were the most utilized biologic therapies in the treatment of PG in 64.8% (70/108), 16.7% (18/108), and 11.1% (12/108) of the cases, respectively. With respect to treatment response, 88.9% (96/108) of the patients achieved complete resolution of PG with biologic therapies. The average number of days to improvement and resolution of PG treated after starting biologic therapies was 30 and 161, respectively. PG recurred in 15.5% (11/71) of those reported the outcome. Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy.
Identifiants
pubmed: 39158753
doi: 10.1007/s00403-024-03332-2
pii: 10.1007/s00403-024-03332-2
doi:
Substances chimiques
Biological Products
0
Infliximab
B72HH48FLU
Etanercept
OP401G7OJC
Adalimumab
FYS6T7F842
Dermatologic Agents
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
539Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR (2010) Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 62(4):646–654
doi: 10.1016/j.jaad.2009.05.030
pubmed: 20227580
Brooklyn TN, Dunnill MGS, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Probert C (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509
doi: 10.1136/gut.2005.074815
pubmed: 16188920
pmcid: 1856164
Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Herrerías-Gutiérrez JM (2013) Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58:2949–2954
doi: 10.1007/s10620-013-2762-2
pubmed: 23828140
Ormerod, A. D., Thomas, K. S., Craig, F. E., Mitchell, E., Greenlaw, N., Norrie, J.,… Williams, H. C. (2015). Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. bmj, 350
Agarwal A, Andrews JM (2013) Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 38(6):563–572
doi: 10.1111/apt.12431
pubmed: 23914999
George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum–a guide to diagnosis and management. Clin Med 19(3):224
doi: 10.7861/clinmedicine.19-3-224
Hobbs MM, Ortega-Loayza AG (2020) Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J 17(5):1255–1265
doi: 10.1111/iwj.13389
pubmed: 32378319
pmcid: 7949187